Even as they sparred on broader healthcare policy and funding topics fueling the ongoing government shutdown, senators of the ...

The Health Resources and Services Administration posted on its website that it had approved eight drug company plans for participation in the 340B Rebate Model Pilot Program with a start date of Jan.

Lawmakers called for more transparency about how hospitals are using 340B revenue, including audits of participating ...

Lawmakers impatient with the lack of progress on a key health care issue — the long-debated need for changes to what’s known ...

Drugs that will be subject to rebates in 340B next year include Bristol Myers Squibb’s Eliquis, Johnson & Johnson’s Stelara ...

The Office of Pharmacy Affairs (OPA) of the Health Resources and Services Administration (HRSA) recently issued a new Program Update that includes new covered entity registration and recertification ...

HRSA requires registration and approval for covered entities to participate in the 340B Program. Facilities that meet the criteria of a Covered Entity apply to participate in the 340B Program by ...

The 340B program presents covered entities with very important financial support to assist with the extension of care to the most vulnerable populations. However, the program is under scrutiny from ...

The Patient Protection and Affordable Care Act is expected to bring significant change to the healthcare industry, including the expansion of the Public Health Service Act Section 340B Program.

Despite the rancor, there are many bipartisan opportunities for the divided 118 th Congress. Near the top of the to-do list should be reforming the well-intentioned, but poorly designed, 340B drug ...

Changes to registration requirements for the offsite clinics of 340B-eligible hospitals represent the latest clash between providers, regulators and drugmakers amid the program’s exponential growth.